Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1993 Dec;52(12):847–850. doi: 10.1136/ard.52.12.847

The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment.

V Kyle 1, B L Hazleman 1
PMCID: PMC1005213  PMID: 8311533

Abstract

OBJECTIVES--To examine the clinical course of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in a prospective study, after the initial two months. METHODS--Seventy four patients with PMR/GCA were followed for a median of 60 weeks. Detailed clinical and laboratory records were made on each visit. RESULTS--Twenty per cent of patients with PMR developed GCA and 24% of patients with GCA developed PMR from the onset of symptoms. After two months, most patients experienced at least one relapse. Relapses and persistence of abnormal symptoms and signs were most common in patients with both PMR and GCA and least common in those with GCA alone. Relapses were most common in the first year and 54% occurred in association with steroid reduction. Major complications were rare. Laboratory parameters and temporal artery histology were not helpful in predicting relapse. Only 24% of patients were able to stop steroid treatment after two years. CONCLUSIONS--Clinicians should consider more frequent review in patients at times of steroid reduction and especially within the first six months of treatment.

Full text

PDF
847

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayoub W. T., Franklin C. M., Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med. 1985 Sep;79(3):309–315. doi: 10.1016/0002-9343(85)90309-2. [DOI] [PubMed] [Google Scholar]
  2. BAGRATUNI L. Anarthritic rheumatoid disease. Lancet. 1956 Oct 6;271(6945):694–697. doi: 10.1016/s0140-6736(56)92384-4. [DOI] [PubMed] [Google Scholar]
  3. BAGRATUNI L. Prognosis in the anarthritic rheumatoid syndrome. Br Med J. 1963 Feb 23;1(5329):513–518. doi: 10.1136/bmj.1.5329.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Behn A. R., Perera T., Myles A. B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis. 1983 Aug;42(4):374–378. doi: 10.1136/ard.42.4.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chuang T. Y., Hunder G. G., Ilstrup D. M., Kurland L. T. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982 Nov;97(5):672–680. doi: 10.7326/0003-4819-97-5-672. [DOI] [PubMed] [Google Scholar]
  6. Fauchald P., Rygvold O., Oystese B. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings. Ann Intern Med. 1972 Dec;77(6):845–852. doi: 10.7326/0003-4819-77-6-845. [DOI] [PubMed] [Google Scholar]
  7. Huston K. A., Hunder G. G., Lie J. T., Kennedy R. H., Elveback L. R. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978 Feb;88(2):162–167. doi: 10.7326/0003-4819-88-2-162. [DOI] [PubMed] [Google Scholar]
  8. Jones J. G., Hazleman B. L. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis. 1981 Feb;40(1):1–5. doi: 10.1136/ard.40.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Knudsen L., Christensen G., Krohn L. Polymyalgia rheumatica syndrome. Scand J Rheumatol. 1982;11(1):17–20. doi: 10.3109/03009748209098107. [DOI] [PubMed] [Google Scholar]
  10. Kyle V., Cawston T. E., Hazleman B. L. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis. 1989 Aug;48(8):667–671. doi: 10.1136/ard.48.8.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kyle V., Hazleman B. L. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989 Aug;48(8):658–661. doi: 10.1136/ard.48.8.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Myles A. B. Polymyalgia rheumatica and giant cell arteritis: a seven-year survey. Rheumatol Rehabil. 1975 Nov;14(4):231–235. doi: 10.1093/rheumatology/14.4.231. [DOI] [PubMed] [Google Scholar]
  13. Park J. R., Jones J. G., Hazleman B. L. Relationship of the erythrocyte sedimentation rate to acute phase proteins in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis. 1981 Oct;40(5):493–495. doi: 10.1136/ard.40.5.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Paulsen S., Iversen T. O. Rheumatic polymyalgia. Long-term treatment with steroids. Acta Rheumatol Scand. 1971;17(3):165–168. doi: 10.3109/rhe1.1971.17.issue-1-4.22. [DOI] [PubMed] [Google Scholar]
  15. Sorensen S., Lorenzen I. Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients. Acta Med Scand. 1977;201(3):207–213. doi: 10.1111/j.0954-6820.1977.tb15683.x. [DOI] [PubMed] [Google Scholar]
  16. WHITFIELD A. G., BATEMAN M., COOKE W. T. TEMPORAL ARTERITIS. Br J Ophthalmol. 1963 Sep;47:555–566. doi: 10.1136/bjo.47.9.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. von Knorring J. Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten-year survey of 53 patients. Acta Med Scand. 1979;205(5):429–435. doi: 10.1111/j.0954-6820.1979.tb06077.x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES